22,095 Shares in Septerna, Inc. (NASDAQ:SEPN) Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new stake in Septerna, Inc. (NASDAQ:SEPN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 22,095 shares of the company’s stock, valued at approximately $506,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SEPN. TRV GP V LLC purchased a new position in Septerna in the fourth quarter valued at $142,337,000. TRV GP VI LLC purchased a new position in Septerna in the fourth quarter valued at $72,191,000. Avoro Capital Advisors LLC purchased a new position in Septerna in the fourth quarter valued at $25,419,000. Vanguard Group Inc. purchased a new position in Septerna in the fourth quarter valued at $22,557,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in Septerna in the fourth quarter valued at $11,877,000.

Insider Activity

In other Septerna news, Director Alan Ezekowitz acquired 41,355 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was bought at an average price of $6.00 per share, with a total value of $248,130.00. Following the purchase, the director now owns 104,101 shares in the company, valued at approximately $624,606. The trade was a 65.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Gil M. Labrucherie acquired 10,500 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The shares were acquired at an average cost of $5.51 per share, with a total value of $57,855.00. Following the purchase, the chief financial officer now owns 10,500 shares in the company, valued at $57,855. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 74,346 shares of company stock worth $439,670 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

SEPN has been the subject of a number of recent analyst reports. Cantor Fitzgerald lifted their price objective on shares of Septerna from $20.00 to $25.00 and gave the company an “overweight” rating in a report on Friday. Wells Fargo & Company lifted their price objective on shares of Septerna from $11.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday.

Septerna Trading Down 2.8%

Shares of NASDAQ SEPN opened at $9.84 on Friday. The company’s 50-day simple moving average is $6.43 and its 200-day simple moving average is $14.27. Septerna, Inc. has a 52-week low of $4.17 and a 52-week high of $28.99.

Septerna (NASDAQ:SEPN) last announced its earnings results on Thursday, May 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The firm had revenue of $0.22 million for the quarter. Equities analysts expect that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.